



(51) International Patent Classification:

C07D 413/04 (2006.01) *A61P 37/00* (2006.01)
A61K 31/4439 (2006.01)

(21) International Application Number:

PCT/IB2012/050241

(22) International Filing Date:

18 January 2012 (18.01.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/IB2011/050241

19 January 2011 (19.01.2011)

IB

(71) **Applicant** (for all designated States except US): **ACTELION PHARMACEUTICALS LTD** [CH/CH]; Gewerbestrasse 16, CH-4123 Allschwil (CH).

(72) **Inventors; and**

(75) **Inventors/Applicants** (for US only): **BOLLI, Martin** [CH/CH]; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). **LESCOP, Cyrille** [FR/FR]; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). **MATHYS, Boris** [CH/CH]; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). **MORRISON, Keith** [GB/FR]; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, F-4123 Allschwil (FR). **MUELLER, Claus** [DE/DE]; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH). **NAYLER, Oliver** [CH/CH]; c/o Actelion Pharmaceuticals Ltd, Gewerbe-

strasse 16, CH-4123 Allschwil (CH). **STEINER, Beat** [CH/CH]; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil (CH).

(74) **Agent**: **GSCHWEND, Thomas**; c/o Actelion Pharmaceuticals Ltd., Legal Department, Gewerbestrasse 16, CH-4123 Allschwil (CH).


(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: 2-METHOXY-PYRIDIN-4-YL DERIVATIVES



(I)

(57) **Abstract:** The invention relates to pyridine derivatives of Formula (I) wherein A, R¹, R², R³, and R⁴ are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.